# BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Study · id `cardio:ct-nct00910065` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT00910065](<https://clinicaltrials.gov/study/NCT00910065>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT00910065

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.

## Technical summary

Registry record NCT00910065. Randomized; no masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 270 participants (enrolled count; ClinicalTrials.gov record NCT00910065, source copy `cardio:ctgov-nct00910065-2015-06-25`, retrieved 2026-10-31)
- Start date: 2011-03 (registry gives no type) (ClinicalTrials.gov record NCT00910065, source copy `cardio:ctgov-nct00910065-2015-06-25`, retrieved 2026-10-31)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT00910065, source copy `cardio:ctgov-nct00910065-2015-06-25`, retrieved 2026-10-31)
- Completion: 2014-07 (actual) (ClinicalTrials.gov record NCT00910065, source copy `cardio:ctgov-nct00910065-2015-06-25`, retrieved 2026-10-31)
- Countries: China; Germany; Russia; Spain (ClinicalTrials.gov record NCT00910065, source copy `cardio:ctgov-nct00910065-2015-06-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct00910065-2015-06-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
- Acronym: ACUTE
- Condition: Acute Coronary Syndrome
- Intervention (Drug): D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV
- Intervention (Drug): D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
- Intervention (Drug): Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 161ee5e13f0276bbb3a0fd03479b28d8794872a0c4380f30fb24fd8a02880410
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
